8-K Announcements
6Material company update
Jun 11, 2026·SEC
Material company update
Apr 29, 2026·SEC
Material company update
Mar 25, 2026·SEC
KalVista Pharmaceuticals faces a challenging transition from a milestone-dependent research entity to a commercial-stage biotechnology firm, characterized by significant operating losses and a deteriorating equity position. While the company maintains a cash b...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q2 2026Latest May 15, 2026 | -$1.08-158.9% vs -$0.42 | $41M+5.4% vs $39M |
Q2 2026 May 7, 2026 | -$0.92-144.5% vs -$0.38 | $14M-65.0% vs $39M |
Q2 2026 May 5, 2026 | -$0.92-144.5% vs -$0.38 | $14M-65.0% vs $39M |
Q2 2026 Mar 25, 2026 | -$0.42+21.3% vs -$0.54 | $14M-59.4% vs $34M |
Benchmark KALV against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for KalVista Pharmaceuticals, Inc. (KALV)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $27.00 | $1.44B | -8.36 | — | -223.16% | -354.52% | — | |
| $1.90 | $108.87M | 4.87 | — | — | -38.8% | — | |
| $282.12 | $7.87B | -20.93 | -100% | — | -34.15% | — | |
| $0.56 | $10.83M | -0.17 | — | — | -187.45% | — | |
| $40.17 | $503.77M | 27.51 | 83.06% | 86.97% | 30.21% | — | |
| $8.40 | $349.8M | -2470.59 | 10.37% | 69.76% | — | — |
KalVista Pharmaceuticals, Inc. (KALV) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
KalVista Pharmaceuticals, Inc. (KALV) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jun 11, 2026·SEC
Apr 29, 2026·SEC
Mar 25, 2026·SEC
Get notified when KALV posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
KalVista Pharmaceuticals, Inc. (KALV) stock FAQ — growth, dividends, profitability & financials explained
KalVista Pharmaceuticals, Inc. (KALV) reported $115.9M in revenue for fiscal year 2026. This represents a 7436% increase from $1.5M in 2013.
KalVista Pharmaceuticals, Inc. (KALV) reported a net loss of $138.4M for fiscal year 2026.
KalVista Pharmaceuticals, Inc. (KALV) has a return on equity (ROE) of -354.5%. Negative ROE indicates the company is unprofitable.
KalVista Pharmaceuticals, Inc. (KALV) had negative free cash flow of $56.6M in fiscal year 2026, likely due to heavy capital investments.